Latest Breaking News On - மருந்துகள் வரையறுக்கப்பட்டவை - Page 27 : comparemela.com

Glenmark becomes the first company to launch Remogliflozin + Vildagliptin fixed dose combination Posted On: 2020-12-29 01:49:21 (Time Zone: Arizona, USA) Glenmark Pharmaceuticals Limited (Glenmark), a research-led global pharmaceutical company has launched a fixed dose combination (FDC) of its novel, patent protected and globally researched Sodium Glucose Co-Transporter Inhibitor (SGLT2i) - Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) - Vildagliptin, in India. The fixed drug combination is indicated for the management of Type 2 diabetes. The combination will contain Remogliflozin (100 mg) + Vildagliptin (50 mg) in a fixed dose and must be taken twice daily to improve glycemic control in patients. Glenmark has launched the same under two brand names Remo V and Remozen V.

United statesGlenmark remogliflozinRemogliflozin etabonateGlenmark remogliflozin vildagiptinRemogliflozin vildagliptinAlok malikGlenmark pharmaceuticals limitedGroup viceSodium glucose coInternational diabetes federationTime zonePharmaceuticals limitedSodium glucose co transporter inhibitorDipeptidyl peptidaseGroup vice presidentBusiness head